Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC

Purpose: The study investigated the impact of TP53 mutations on the clinical efficacy of first-generation EGFR-tyrosine kinase inhibitors (TKIs) in Chinese patients with advanced or recurrent non-small-cell lung cancer (NSCLC). Patients and methods: Tissues from 163 NSCLC patients at the Affiliated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Manag Res
Main Authors: Hou, Helei, Qin, Kang, Liang, Yu, Zhang, Chuantao, Liu, Dong, Jiang, Haiping, Liu, Kewei, Zhu, Jingjuan, Lv, Hongying, Li, Tianjun, Zhang, Xiaochun
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594053/
https://ncbi.nlm.nih.gov/pubmed/31417310
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S201513
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados